AVIR — Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Cash Position: Atea reported $256 million in cash and marketable securities as of March 31, 2026, providing a strong financial foundation to support ongoing clinical programs.
• R&D Expenses: Increased R&D expenses driven by external spending related to Phase III clinical development for HCV and preclinical development for HEV.
• G&A Expenses: Decreased due to lower salaries, stock-based compensation, and professional fees.

2. Strategic Updates and Business Highlights

• HCV Program:
  • Completed enrollment for the C-BEYOND trial (North America) with over 880 patients and expects top-line data mid-2026.
  • The C-FORWARD trial (ex-North America) is 95% enrolled and anticipated to complete by mid-year, with results expected by year-end.
  • The regimen (bemnifosbuvir and ruzasvir) shows potential for high efficacy, short treatment duration, and low risk of drug interactions.
• HEV Program:
  • Atea is advancing AT-587, a potential first-in-class treatment for chronic hepatitis E, with a first-in-human study expected to initiate mid-2026.
  • The unmet need for HEV treatment in immunocompromised patients represents a significant market opportunity, estimated between $750 million to $1 billion annually.

3. Forward Guidance and Outlook

• Cash Runway: The company expects its cash runway to extend through 2027, allowing for continued investment in both HCV and HEV programs.
• Clinical Milestones: Anticipates delivering top-line results from C-BEYOND in mid-2026 and C-FORWARD by year-end 2026, which are critical for regulatory submissions and potential commercialization.

4. Bad News, Challenges, or Points of Concern

• Market Competition: The HCV market remains competitive, with existing therapies like Epclusa and Mavyret. Atea's success will depend on demonstrating superior efficacy and safety profiles in Phase III trials.
• Regulatory Risks: The outcomes of the Phase III trials are crucial; any unfavorable results could impact market entry and adoption.
• Adoption Barriers: Commercial launch may face challenges related to contracting and integration into existing treatment pathways, particularly in the context of the test-and-treat model.

5. Notable Q&A Insights

• Data Expectations: Top-line announcements for C-BEYOND will include primary and key secondary efficacy endpoints, while detailed analyses will follow in peer-reviewed settings.
• Commercial Readiness: Preparations for market entry are underway, focusing on understanding payer dynamics and formulary access, which will be critical for adoption.
• Phase III Expectations: There is confidence that Phase III results will align with positive Phase II data, particularly regarding efficacy and low drug interaction potential.
• AT-587 Study Design: The first-in-human study for AT-587 will evaluate safety and pharmacokinetics, with a treatment duration of 12 weeks anticipated for the proof-of-concept study.

Overall, Atea Pharmaceuticals is positioned for a pivotal year with significant clinical milestones ahead, while also navigating competitive and regulatory challenges in the HCV and HEV markets.